Crystal structure of the human 20S proteasome in complex with carfilzomib

Structure

Volumn 23, Issue 2, 2015, Pages 418-424

  Harshbarger, Wayne ^a   Miller, Chase ^a   Diedrich, Chandler ^a   Sacchettini, James ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20S PROTEASOME; CARFILZOMIB; CHYMOTRYPSIN; PROTEASOME; UNCLASSIFIED DRUG; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CATALYSIS; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ERYTHROCYTE; HUMAN; HUMAN CELL; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; MOUSE; SPECIES DIFFERENCE;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; SPECIES SPECIFICITY;

EID: 84930188528     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2014.11.017     Document Type: Article

References (21)

1. J.A. Brannigan, G. Dodson, H.J. Duggleby, P.C. Moody, J.L. Smith, D.R. Tomchick, and A.G. Murzin A protein catalytic framework with an N-terminal nucleophile is capable of self-activation Nature 378 1995 416 419
2. D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, and A. Letai A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 8 2005 407 419
3. S.D. Demo, C.J. Kirk, M.A. Aujay, T.J. Buchholz, M. Dajee, M.N. Ho, J. Jiang, G.J. Laidig, E.R. Lewis, and F. Parlati Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res. 67 2007 6383 6391
4. T.P. Dick, A.K. Nussbaum, M. Deeg, W. Heinemeyer, M. Groll, M. Schirle, W. Keilholz, S. Stevanovic, D.H. Wolf, and R. Huber Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants J. Biol. Chem. 273 1998 25637 25646
5. T.A. Griffin, D. Nandi, M. Cruz, H.J. Fehling, L.V. Kaer, J.J. Monaco, and R.A. Colbert Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits J. Exp. Med. 187 1998 97 104
6. M. Groettrup, C.J. Kirk, and M. Basler Proteasomes in immune cells: more than peptide producers? Nat. Rev. Immunol. 10 2010 73 78
7. M. Groettrup, R. Kraft, S. Kostka, S. Standera, R. Stohwasser, and P.M. Kloetzel A third interferon-gamma-induced subunit exchange in the 20S proteasome Eur. J. Immunol. 26 1996 863 869
8. M. Groll, L. Ditzel, J. Lowe, D. Stock, M. Bochtler, H.D. Bartunik, and R. Huber Structure of 20S proteasome from yeast at 2.4 A resolution Nature 386 1997 463 471
9. M. Groll, K.B. Kim, N. Kairies, R. Huber, and C.M. Crews Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha ',beta '-epoxyketone proteasome inhibitors J. Am. Chem. Soc. 122 2000 1237 1238
10. M. Groll, R. Huber, and B.C. Potts Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding J. Am. Chem. Soc. 128 2006 5136 5141
11. E.M. Huber, M. Basler, R. Schwab, W. Heinemeyer, C.J. Kirk, M. Groettrup, and M. Groll Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity Cell 148 2012 727 738
12. M. Jullig, W.V. Zhang, A. Ferreira, and N.S. Stott MG132 induced apoptosis is associated with p53-independent induction of pro-apoptotic Noxa and transcriptional activity of beta-catenin Apoptosis 11 2006 627 641
13. A.F. Kisselev, T.N. Akopian, V. Castillo, and A.L. Goldberg Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown Mol. Cell 4 1999 395 402
14. T.A. McCormack, A.A. Cruikshank, L. Grenier, F.D. Melandri, S.L. Nunes, L. Plamondon, R.L. Stein, and L.R. Dick Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone Biochemistry 37 1998 7792 7800
15. S. Murata, K. Sasaki, T. Kishimoto, S. Niwa, H. Hayashi, Y. Takahama, and K. Tanaka Regulation of CD8+ T cell development by thymus-specific proteasomes Science 316 2007 1349 1353
16. T. Nitta, S. Murata, K. Sasaki, H. Fujii, A.M. Ripen, N. Ishimaru, S. Koyasu, K. Tanaka, and Y. Takahama Thymoproteasome shapes immunocompetent repertoire of CD8+ T cells Immunity 32 2010 29 40
17. M. Screen, M. Britton, S.L. Downey, M. Verdoes, M.J. Voges, A.E. Blom, P.P. Geurink, M.D. Risseeuw, B.I. Florea, and W.A. van der Linden Nature of pharmacophore influences active site specificity of proteasome inhibitors J. Biol. Chem. 285 2010 40125 40134
18. M. Unno, T. Mizushima, Y. Morimoto, Y. Tomisugi, K. Tanaka, N. Yasuoka, and T. Tsukihara The structure of the mammalian 20S proteasome at 2.75 A resolution Structure 10 2002 609 618
19. D. Voges, P. Zwickl, and W. Baumeister The 26S proteasome: a molecular machine designed for controlled proteolysis Annu. Rev. Biochem. 68 1999 1015 1068
20. P.M. Voorhees, E.C. Dees, B. O'Neil, and R.Z. Orlowski The proteasome as a target for cancer therapy Clin. Cancer. Res. 9 2003 6316 6325
21. H.J. Zhou, M.A. Aujay, M.K. Bennett, M. Dajee, S.D. Demo, Y. Fang, M.N. Ho, J. Jiang, C.J. Kirk, and G.J. Laidig Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J. Med. Chem. 52 2009 3028 3038